Switch theme
Sign up to access all valuation multiples
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
2007
1.5K+
LTM Revenue $586M
LTM EBITDA $175M
$6.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Salubris Pharmaceuticals has a last 12-month revenue (LTM) of $586M and a last 12-month EBITDA of $175M.
In the most recent fiscal year, Salubris Pharmaceuticals achieved revenue of $557M and an EBITDA of $142M.
Salubris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Salubris Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $586M | XXX | $557M | XXX | XXX | XXX |
| Gross Profit | $426M | XXX | $405M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $175M | XXX | $142M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $97.0M | XXX | $107M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $87.7M | XXX | $83.5M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Salubris Pharmaceuticals's stock price is CNY 45 (or $6).
Salubris Pharmaceuticals has current market cap of CNY 50.7B (or $7.0B), and EV of CNY 48.9B (or $6.8B).
See Salubris Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.8B | $7.0B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Salubris Pharmaceuticals has market cap of $7.0B and EV of $6.8B.
Salubris Pharmaceuticals's trades at 12.2x EV/Revenue multiple, and 47.8x EV/EBITDA.
Equity research analysts estimate Salubris Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Salubris Pharmaceuticals has a P/E ratio of 80.1x.
See valuation multiples for Salubris Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.0B | XXX | $7.0B | XXX | XXX | XXX |
| EV (current) | $6.8B | XXX | $6.8B | XXX | XXX | XXX |
| EV/Revenue | 11.6x | XXX | 12.2x | XXX | XXX | XXX |
| EV/EBITDA | 38.8x | XXX | 47.8x | XXX | XXX | XXX |
| EV/EBIT | 70.0x | XXX | 63.5x | XXX | XXX | XXX |
| EV/Gross Profit | 16.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 80.1x | XXX | 84.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 87.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSalubris Pharmaceuticals's last 12 month revenue growth is 16%
Salubris Pharmaceuticals's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Salubris Pharmaceuticals's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Salubris Pharmaceuticals's rule of X is 70% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Salubris Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Salubris Pharmaceuticals acquired XXX companies to date.
Last acquisition by Salubris Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Salubris Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Salubris Pharmaceuticals founded? | Salubris Pharmaceuticals was founded in 2007. |
| Where is Salubris Pharmaceuticals headquartered? | Salubris Pharmaceuticals is headquartered in China. |
| How many employees does Salubris Pharmaceuticals have? | As of today, Salubris Pharmaceuticals has 1.5K+ employees. |
| Is Salubris Pharmaceuticals publicy listed? | Yes, Salubris Pharmaceuticals is a public company listed on SHE. |
| What is the stock symbol of Salubris Pharmaceuticals? | Salubris Pharmaceuticals trades under 002294 ticker. |
| When did Salubris Pharmaceuticals go public? | Salubris Pharmaceuticals went public in 2009. |
| Who are competitors of Salubris Pharmaceuticals? | Similar companies to Salubris Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Salubris Pharmaceuticals? | Salubris Pharmaceuticals's current market cap is $7.0B |
| What is the current revenue of Salubris Pharmaceuticals? | Salubris Pharmaceuticals's last 12 months revenue is $586M. |
| What is the current revenue growth of Salubris Pharmaceuticals? | Salubris Pharmaceuticals revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Salubris Pharmaceuticals? | Current revenue multiple of Salubris Pharmaceuticals is 11.6x. |
| Is Salubris Pharmaceuticals profitable? | Yes, Salubris Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Salubris Pharmaceuticals? | Salubris Pharmaceuticals's last 12 months EBITDA is $175M. |
| What is Salubris Pharmaceuticals's EBITDA margin? | Salubris Pharmaceuticals's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Salubris Pharmaceuticals? | Current EBITDA multiple of Salubris Pharmaceuticals is 38.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
